• MoonLake Immunotherapeutics posted a net loss of $61.81 million, widening 10.3% year over year in the quarter ended June 30, 2026.
• Operating loss widened 1.6% to $61.66 million as research and development spending edged up 0.9% to $50.22 million.
• General and administrative costs rose 4.6% to $11.44 million, while other income fell 62% to $2.58 million.
• Cash, cash equivalents, and short-term marketable securities totaled $537 million at June 30, funding operations to mid-2028.
• MoonLake targets a BLA submission for sonelokimab in hidradenitis suppurativa at end-Q3 2026, aiming for a U.S. launch in H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001821586-26-000010), on August 10, 2026, and is solely responsible for the information contained therein.